Cardioprotective effects of sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase 4 inhibitor in type 2 diabetes: A meta-analysis of comparative safety and efficacy.

Abhigan Babu ShresthaAnupam HalderKripa RajakSaroj Kumar JhaRamesh LamichhaneArefin Naher OisheeNayanika Tummala ChowdaryPashupati PokharelSajina ShresthaLukash AdhikariBikash AdhikariAman RajakJalal Haider KhanNischal Mainali

Published in: SAGE open medicine (2024)

Our findings suggest that compared to dipeptidyl peptidase 4 inhibitor, initiating treatment with sodium glucose cotransporter 2 inhibitors provides cardiovascular disease protection and may be considered in patients with type 2 diabetes.

Keyphrases

type diabetes
cardiovascular disease
insulin resistance
metabolic syndrome
combination therapy